Syntra-5 downregulates inflammatory signaling in obese type 2 diabetes murine model in vivo

Robert T. Streeper, Armando Diaz, David Campos, Joel E Michalek, Christopher Louden, Wieslaw Furmaga, Elzbieta Izbicka

Research output: Contribution to journalArticle

Abstract

We compared anti-inflammatory activity of Syntra-5, an herbal dietary supplement, versus metformin, Actos (pioglitazone hydrochloride), and Byetta (exenatide) in obese diabetic BKS.Cg-m+/Leprdb/Bom Tac female mice (8 per group, including controls) on normal diet (ND) or high fat diet (HFD) +/- drugs for 8 weeks. We measured plasma levels of 40 biomarkers [chemokines, cytokines, endocrine markers, growth factors and metabolites including glucose, insulin, advanced glycation end product (AGE), cholesterol and triglycerides]. Pyruvate kinase activity, citrate, ADP and A TP and hexokinase II levels were determined in muscle. Organ pathology was assessed microscopically. Mean values of biomarkers were compared between treatment groups. Biomarker means varied significantly by treatment group and diet. Syntra-5 decreased levels of eotaxin, MCP-1, MCP-3, M-CSF, and increased IL-4 (ND), and decreased G-CSF, GM-CSF, and TGF2 (HFD) relative to controls. Pyruvate kinase and AGE increased, while insulin decreased in Syntra-5-treated animals relative to untreated on ND. Treatment group contrasts on biomarkers (MCP-3, IL-17, AGE, and insulin) also varied with diet. Syntra-5 decreased progression of histopathological changes versus all groups. Syntra-5 demonstrated superior anti-inflammatory activity relative to the anti-diabetic drugs on a background of genetic obesity, supporting the contention that Syntra-5 may be effective for type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCurrent Topics in Nutraceutical Research
Volume9
Issue number1-2
StatePublished - 2011

Fingerprint

Type 2 Diabetes Mellitus
pioglitazone
Down-Regulation
Advanced Glycosylation End Products
Diet
Biomarkers
Pyruvate Kinase
High Fat Diet
Insulin
Granulocyte-Macrophage Colony-Stimulating Factor
Chemokine CCL11
Anti-Inflammatory Agents
Hexokinase
Macrophage Colony-Stimulating Factor
Interleukin-17
Metformin
Granulocyte Colony-Stimulating Factor
Dietary Supplements
Chemokines
Citric Acid

Keywords

  • Biomarker
  • Diabetes
  • Herbal supplement
  • Inflammation
  • Mouse
  • Syntra-5

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Streeper, R. T., Diaz, A., Campos, D., Michalek, J. E., Louden, C., Furmaga, W., & Izbicka, E. (2011). Syntra-5 downregulates inflammatory signaling in obese type 2 diabetes murine model in vivo. Current Topics in Nutraceutical Research, 9(1-2), 1-12.

Syntra-5 downregulates inflammatory signaling in obese type 2 diabetes murine model in vivo. / Streeper, Robert T.; Diaz, Armando; Campos, David; Michalek, Joel E; Louden, Christopher; Furmaga, Wieslaw; Izbicka, Elzbieta.

In: Current Topics in Nutraceutical Research, Vol. 9, No. 1-2, 2011, p. 1-12.

Research output: Contribution to journalArticle

Streeper, RT, Diaz, A, Campos, D, Michalek, JE, Louden, C, Furmaga, W & Izbicka, E 2011, 'Syntra-5 downregulates inflammatory signaling in obese type 2 diabetes murine model in vivo', Current Topics in Nutraceutical Research, vol. 9, no. 1-2, pp. 1-12.
Streeper, Robert T. ; Diaz, Armando ; Campos, David ; Michalek, Joel E ; Louden, Christopher ; Furmaga, Wieslaw ; Izbicka, Elzbieta. / Syntra-5 downregulates inflammatory signaling in obese type 2 diabetes murine model in vivo. In: Current Topics in Nutraceutical Research. 2011 ; Vol. 9, No. 1-2. pp. 1-12.
@article{829d1586af8c4f3885a8f9e265e1169a,
title = "Syntra-5 downregulates inflammatory signaling in obese type 2 diabetes murine model in vivo",
abstract = "We compared anti-inflammatory activity of Syntra-5, an herbal dietary supplement, versus metformin, Actos (pioglitazone hydrochloride), and Byetta (exenatide) in obese diabetic BKS.Cg-m+/Leprdb/Bom Tac female mice (8 per group, including controls) on normal diet (ND) or high fat diet (HFD) +/- drugs for 8 weeks. We measured plasma levels of 40 biomarkers [chemokines, cytokines, endocrine markers, growth factors and metabolites including glucose, insulin, advanced glycation end product (AGE), cholesterol and triglycerides]. Pyruvate kinase activity, citrate, ADP and A TP and hexokinase II levels were determined in muscle. Organ pathology was assessed microscopically. Mean values of biomarkers were compared between treatment groups. Biomarker means varied significantly by treatment group and diet. Syntra-5 decreased levels of eotaxin, MCP-1, MCP-3, M-CSF, and increased IL-4 (ND), and decreased G-CSF, GM-CSF, and TGF2 (HFD) relative to controls. Pyruvate kinase and AGE increased, while insulin decreased in Syntra-5-treated animals relative to untreated on ND. Treatment group contrasts on biomarkers (MCP-3, IL-17, AGE, and insulin) also varied with diet. Syntra-5 decreased progression of histopathological changes versus all groups. Syntra-5 demonstrated superior anti-inflammatory activity relative to the anti-diabetic drugs on a background of genetic obesity, supporting the contention that Syntra-5 may be effective for type 2 diabetes.",
keywords = "Biomarker, Diabetes, Herbal supplement, Inflammation, Mouse, Syntra-5",
author = "Streeper, {Robert T.} and Armando Diaz and David Campos and Michalek, {Joel E} and Christopher Louden and Wieslaw Furmaga and Elzbieta Izbicka",
year = "2011",
language = "English (US)",
volume = "9",
pages = "1--12",
journal = "Current Topics in Nutraceutical Research",
issn = "1540-7535",
publisher = "New Century Health Publishers",
number = "1-2",

}

TY - JOUR

T1 - Syntra-5 downregulates inflammatory signaling in obese type 2 diabetes murine model in vivo

AU - Streeper, Robert T.

AU - Diaz, Armando

AU - Campos, David

AU - Michalek, Joel E

AU - Louden, Christopher

AU - Furmaga, Wieslaw

AU - Izbicka, Elzbieta

PY - 2011

Y1 - 2011

N2 - We compared anti-inflammatory activity of Syntra-5, an herbal dietary supplement, versus metformin, Actos (pioglitazone hydrochloride), and Byetta (exenatide) in obese diabetic BKS.Cg-m+/Leprdb/Bom Tac female mice (8 per group, including controls) on normal diet (ND) or high fat diet (HFD) +/- drugs for 8 weeks. We measured plasma levels of 40 biomarkers [chemokines, cytokines, endocrine markers, growth factors and metabolites including glucose, insulin, advanced glycation end product (AGE), cholesterol and triglycerides]. Pyruvate kinase activity, citrate, ADP and A TP and hexokinase II levels were determined in muscle. Organ pathology was assessed microscopically. Mean values of biomarkers were compared between treatment groups. Biomarker means varied significantly by treatment group and diet. Syntra-5 decreased levels of eotaxin, MCP-1, MCP-3, M-CSF, and increased IL-4 (ND), and decreased G-CSF, GM-CSF, and TGF2 (HFD) relative to controls. Pyruvate kinase and AGE increased, while insulin decreased in Syntra-5-treated animals relative to untreated on ND. Treatment group contrasts on biomarkers (MCP-3, IL-17, AGE, and insulin) also varied with diet. Syntra-5 decreased progression of histopathological changes versus all groups. Syntra-5 demonstrated superior anti-inflammatory activity relative to the anti-diabetic drugs on a background of genetic obesity, supporting the contention that Syntra-5 may be effective for type 2 diabetes.

AB - We compared anti-inflammatory activity of Syntra-5, an herbal dietary supplement, versus metformin, Actos (pioglitazone hydrochloride), and Byetta (exenatide) in obese diabetic BKS.Cg-m+/Leprdb/Bom Tac female mice (8 per group, including controls) on normal diet (ND) or high fat diet (HFD) +/- drugs for 8 weeks. We measured plasma levels of 40 biomarkers [chemokines, cytokines, endocrine markers, growth factors and metabolites including glucose, insulin, advanced glycation end product (AGE), cholesterol and triglycerides]. Pyruvate kinase activity, citrate, ADP and A TP and hexokinase II levels were determined in muscle. Organ pathology was assessed microscopically. Mean values of biomarkers were compared between treatment groups. Biomarker means varied significantly by treatment group and diet. Syntra-5 decreased levels of eotaxin, MCP-1, MCP-3, M-CSF, and increased IL-4 (ND), and decreased G-CSF, GM-CSF, and TGF2 (HFD) relative to controls. Pyruvate kinase and AGE increased, while insulin decreased in Syntra-5-treated animals relative to untreated on ND. Treatment group contrasts on biomarkers (MCP-3, IL-17, AGE, and insulin) also varied with diet. Syntra-5 decreased progression of histopathological changes versus all groups. Syntra-5 demonstrated superior anti-inflammatory activity relative to the anti-diabetic drugs on a background of genetic obesity, supporting the contention that Syntra-5 may be effective for type 2 diabetes.

KW - Biomarker

KW - Diabetes

KW - Herbal supplement

KW - Inflammation

KW - Mouse

KW - Syntra-5

UR - http://www.scopus.com/inward/record.url?scp=84886933031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886933031&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84886933031

VL - 9

SP - 1

EP - 12

JO - Current Topics in Nutraceutical Research

JF - Current Topics in Nutraceutical Research

SN - 1540-7535

IS - 1-2

ER -